# MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)

> **NCT00532935** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 517 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** sitagliptin phosphate (+) metformin hydrochloride
- **DRUG:** Comparator: pioglitazone

## Key facts

- **NCT ID:** NCT00532935
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01-26
- **Primary completion:** 2009-10-23
- **Final completion:** 2009-10-23
- **Target enrollment:** 517 (ACTUAL)
- **Last updated:** 2017-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532935, "MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00532935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*